OR1L8

Across TCGA pan-cancer cohorts, OR1L8 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated OR1L8 data layer compared with 18 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher OR1L8 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated OR1L8 expression acts as an unfavorable survival marker.

HNSC, OV, and LIHC are the cancer types where OR1L8 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	OS	Median	IV	0.082	0.708	<.001	45	view →
OV	DFS	Median	All	0.092	0.541	<.001	18	view →
LIHC	OS	Median	All	0.031	0.777	<.001	12	view →
LGG	OS	Median	All	0.173	0.830	<.001	8	view →
UCEC	OS	Median	IV	0.231	0.592	.036	6	view →
SKCM	OS	Median	IV	0.589	0.754	.023	2	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

OR1L8–HNSC (OS)

Open the HNSC breakdown →